MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

06/08/2019
MorphoSys AG Reports Second Quarter 2019 Financial Results
06/08/2019
MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND...
06/08/2019
MorphoSys Announces Intention to Submit Marketing Authorization...
25/07/2019
Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019
08/07/2019
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule...
03/07/2019
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program...
03/07/2019
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a...
24/06/2019
Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc:...
24/06/2019
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
24/06/2019
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive...

August 28, 2019
Commerzbank Sector Conference 2018
Frankfurt, Germany

See conference

We are looking forward to welcoming Dr. Jean-Paul Kress as new MorphoSys CEO on September 1, 2019.

SEE OUR MEDIA RELEASE

 

 

 

 

Interview with
Simon Moroney, CEO